Benzinga
16 Sept 2026, 09:04 UTC · 6w ago
Impact · against what's priced in
Tempest Therapeutics (TPST) gains a material catalyst via an exclusive option for a CAR-T pipeline and a Phase 1 multiple myeloma candidate, diversifying its clinical risk. Other mentioned tickers are merely listed as pre-market movers without fundamental drivers provided in the text.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Tempest Therapeutics entered an exclusive option agreement with Hebei Senlang Biotechnology to license a CD7-targeted lentiviral vector platform and an in vivo CAR-T pipeline.
Newannounced in the news cycle of Sep 16
So whatThe addition of a Phase 1 dual-targeting candidate for multiple myeloma diversifies the clinical-stage pipeline and may reduce binary risk for the company's valuation.
More positive than 99% of claims this week
Continue reading
5 related stories
The exclusive option agreement to license a CD7-targeted lentiviral vector platform and a Phase 1 dual-targeting candidate for multiple myeloma expands the company's clinical-stage pipeline.
Read from the article alone
No priced-in read yet
The article mentions the stock is trading lower in pre-market but provides no fundamental reason for the move.
Read from the article alone
No priced-in read yet
The article mentions the stock is trading higher in pre-market but provides no fundamental reason for the move.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Tempest Therapeutics shares rose 49.6% to $1.13 in pre-market trading following the licensing announcement.
Newpre-market trading on Sep 16
More positive than 76% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Shares rose nearly 50% following an exclusive option agreement for a CAR-T pipeline.
More positive than 87% of ticker scores this week
Stock price is trading significantly higher in pre-market trading.
More negative than 87% of ticker scores this week
Stock price is trading significantly lower in pre-market trading.
More positive than 75% of ticker scores this week
Stock price is trading higher in pre-market trading.
More negative than 85% of ticker scores this week
Stock price is trading significantly lower in pre-market trading.
More positive than 68% of ticker scores this week
Stock price is trading higher in pre-market trading.
More positive than 64% of ticker scores this week
Stock price is trading higher in pre-market trading.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
20h ago
−34.4%
Price is moving against the score
$0.4955 vs $0.7554 close before publication (Sep 15) · not market-adjusted
TPST chart →−77.2%
$2.11 vs $9.27 close before publication (Sep 15) · not market-adjusted
CTNT chart →+18.5%
$1.92 vs $1.62 close before publication (Sep 15) · not market-adjusted
MEDS chart →
